

**P&T Motion History
Targeted Immune Modulators (TIMs)**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate Update	Reiteration of Prior Motion	Decision
abatacept adalimumab alefacept anakinra apremilast canakinumab certolizumab pegol etanercept golimumab infliximab natalizumab rituximab secukinumab tocilizumab tofacitinib ustekinumab vedolizumab	After considering the evidence of safety, efficacy, effectiveness and special populations for the use of targeted immune modulators for the treatment of immunologic conditions for which they have FDA indications, I move that: abatacept, adalimumab, alefacept, anakinra, apremilast, canakinumab, certolizumab pegol, etanercept, golimumab, infliximab, natalizumab, rituximab, secukinumab, tocilizumab, tofacitinib, ustekinumab, vedolizumab are efficacious. The PDL must include a drug approved for treatment of the following FDA indications (rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis) and should include a self-administered agent if indicated. These medications cannot be subject to therapeutic interchange in the Washington preferred drug list. Motion: Bowman 2 nd : Harvey	August 17, 2016	NA	No	Passed unanimous

Bold = new this update
 *=drugs not reviewed
8/18/2016